๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› India
Clinical trial register · India

Studies with an Indian investigative site

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1125 matching records held by the registry are in this view. Synced 22 Sep 2026, 03:16 UTC
1125
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
Kolkata 54 Delhi 40 Bangalore 39 New Delhi 38 Mumbai 37
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca100 Institute of Liver and Biliary Sciences, India48 Postgraduate Institute of Dental Sciences Rohtak45 Novartis Pharmaceuticals44 Tata Memorial Centre41 Clear sponsor filter
Site location
Kolkata54 Delhi40 Bangalore39 New Delhi38 Mumbai37
All 76 locations
Target enrolment
to
100 of 1125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
AstraZeneca
Phase 3
600
Ahmedabad, Bangalore, Gurgaon, Kottayam, Madurai, Nashik, New Delhi, Vadodara
2026-09-29
Not yet open
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
AstraZeneca
Phase 3
1,072
Kolkata
2026-09-01
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Belagavi, Calicut, Coimbatore, Dehradun, Delhi, Hyderabad, Jaipur, Kanpur
2026-08-24
Not yet open
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
1,500
Bangalore, Indore, Kolkata, Nagpur, Pune, Siliguri, Visakhapatnam
2026-08-21
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
AstraZeneca
Phase 3
7,000
Aligarh, Bangalore, Belagavi, Bhubaneswar, Calicut, Chennai, Dehradun, Delhi
2026-08-21
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
AstraZeneca
Phase 3
2,500
Bhubaneswar, Coimbatore, Hyderabad, Indore, Jaipur, Jodhpur, Kochi, Kolkata
2026-08-19
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
AstraZeneca
Phase 3
230
Ahmedabad, Ajmer
2026-07-24
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca
Phase 3
915
Kolkata, Kottayam, Nashik, Navi Mumbai, New Delhi
2026-07-16
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
600
Bangalore, Belagavi, Chennai, Coimbatore, Guntur, Hyderabad, Indore, Kochi
2026-07-08
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
2,000
Bangalore, Belagavi, Calicut, Chennai, Coimbatore, Guwahati, Indore, Jaipur
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
AstraZeneca
Phase 3
900
Aligarh, Belagavi, Belgavi, Calicut, Chennai, Coimbatore, Delhi, Guntur
2026-07-06
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
AstraZeneca
Phase 3
4,500
Bangalore, Belagavi, Bikaner, Delhi, Guntur, Hyderabad, Jaipur, Jodhpur
2026-06-29
Recruiting
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
NCT07606066Type 2 Diabetes
AstraZeneca
Observational
2,150
Guntur, Guwahati, Bangalore, Belagavi, Calicut, Kochi, Thiruvananthapuram, Indore
2026-05-06
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3
670
Bangalore, Gurgaon, Navi Mumbai
2026-05-04
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Ahmedabad, Bhubaneswar, Hyderabad, Kolkata, Mohali, Mumbai, New Delhi, Varanasi
2026-02-03
Recruiting
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
NCT06531798Moderate to Severe COPD
AstraZeneca
Phase 4
150
Dalgate, Drugjan, Hyderabad, Lucknow, Nagpur, New Delhi
2026-01-30
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Bhubaneswar, Chennai, Delhi, Dhanvantari Nagar, Kolkata, Nagpur, Nashik, Surat
2025-12-29
Active, closed
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
NCT06851806Respiratory Syncytial Virus (RSV)
AstraZeneca
Not applicable
21
Hyderabad, Jhฤnsi, Kanpur, Kolkata, Mysore, Nagpur, Pune, Vidyanagar, Hubballi
2025-12-10
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Delhi, Hyderabad, Kolhฤpur, Kolkata, Mumbai, Nashik, Surat
2025-12-04
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 3
400
Bangalore, Kolkata, Mumbai, Nashik, New Delhi
2025-10-31
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Belagavi, Delhi, Hyderabad, Kolkata, Mumbai
2025-08-07
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Ansฤrinagar, Babgalore, Calicut, Delhi, Hyderabad, Kannur, Kanpur, Mumbai
2025-08-06
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Belagavi, Coimbatore, Dehradun, Delhi, Dwฤrka, Hyderabad, Kochi, Mumbai
2025-06-27
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
AstraZeneca
Phase 3
15,100
Ahmedabad, Aurangabad, Bangalore, Belagavi, Bikaner, Calicut, Chennai, Coimbatore
2025-06-04
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123Cardiovascular Disease
AstraZeneca
Phase 3
3,103
Belagavi, Dehradun, Kanpur, Kochi, New Delhi
2025-05-28
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,220
Ahmedabad, Bangalore, Binnฤguri, Dehradun, Delhi, Hyderabad, Mumbai, Nashik
2025-05-06
Recruiting
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
AstraZeneca
Phase 3
14
Ahmedabad
2025-04-17
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
AstraZeneca
Phase 2
540
Belagavi, Coimbatore, Dehradun, Delhi, Faridabad, Gurgaon, Kochi, Lucknow
2025-03-26
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 3
990
Ahmedabad, Aligarh, Belagavi, Coimbatore, Dehradun, Delhi, Dwฤrka, Faridabad
2025-03-18
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Ahmedabad, Ajmer, Bangalore, Belagavi, Dehradun, Delhi, Gurgaon, Hyderabad
2025-03-14
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Bangalore, Belagavi, Hyderabad, Kolkata, Madurai, Mumbai, New Delhi, Pune
2025-03-03
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Ansฤrinagar, Bangalore, Delhi, Hyderabad, Kolkata, Mumbai, Varanasi
2025-03-01
Active, closed
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
NCT06429761BREAST CANCER
AstraZeneca
Phase 4
100
Bangalore, Delhi, Kochi, Mumbai, New Delhi, Pune, Varanasi
2025-01-02
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-18
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
744
Amravati, Bhubaneswar, Hyderabad, Kolhฤpur, Mumbai, Mysuru, Namakkal, Pune
2024-10-04
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
AstraZeneca
Phase 3
620
Dehradun, Delhi, Kanpur, Kolkata, Mumbai, Vadodara, Varanasi
2024-08-12
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
Delhi, Gurugram, Kolkata, Nashik, Surat, Thiruvananthapuram
2024-08-07
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Ahmedabad, Dehradun, Delhi, Gurugram, Hyderabad, Kolkata, Lucknow, Mumbai
2024-06-20
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Ahmedabad, Ajmer, Amritsar, Bangalore, Belagavi, Coimbatore, Dehradun, Delhi
2024-04-12
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Chennai, Dwฤrka, Jaipur, Kolkata, Marg Jaipur, Nagpur, Nashik, New Delhi
2024-04-11
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Bangalore, Belagavi, Calicut, Chennai, Coimbatore, Dehradun, Hyderabad, Kolkata
2024-03-29
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca
Phase 3
594
Ahmedabad, Hyderabad, Mumbai, New Delhi
2024-03-04
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Ahmedabad, Aligarh, Belagavi, Calicut, Chandigarh, Dehradun, Delhi, Dwฤrka
2024-02-21
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Bengaluru, Hyderabad, Jaipur, Kanpur, Kochi, Kolkata, Lucknow, Madurai
2023-12-14
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Delhi, Kolkata, Mumbai, Mysuru, New Delhi, Varanasi
2023-12-04
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
AstraZeneca
Phase 3
625
Calicut, Chennai, Jaipur, Kochi, Kolkata, Kottayam, Marg Jaipur, Mohali
2023-11-23
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Bangalore, Calicut, Kanpur, Kolkata, Nagpur, New Delhi, Pune, Vadodara
2023-11-21
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Bengaluru, Delhi, Kolkata, Marg Jaipur, Nagpur, Nashik, Thiruvananthapuram, Vadodara
2023-11-14
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Ahmedabad, Delhi, Gurugram, Hyderabad, Kolkata, Mumbai, Mysuru, New Delhi
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Bangalore, Belagavi, Delhi, Nadiฤd, New Delhi
2023-11-07
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
895
Bengaluru, Hyderabad, Kolkata, Mysuru, Nagpur, Varanasi
2023-10-24
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
5,511
Ansฤrinagar, Bangalore, Dehradun, Delhi, Kolkata, Kozhikode, Mumbai, Mysuru
2023-10-05
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
AstraZeneca
Phase 3
800
Calicut, Jaipur, Lucknow, Madurai, Mohali, Nagpur, Nashik, New Delhi
2023-09-22
Active, closed
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
NCT05817110Lung Malignancy
AstraZeneca
Observational
712
Gurugram, New Delhi, Hyderabad, Bangalore, Chennai, Kolkata, Mumbai, Pune
2023-04-20
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Bangalore, Belagavi, Bhubaneswar, Hubli, Hyderabad, Jaipur, Kolkata, Mumbai
2023-03-31
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Calicut, Delhi, Jaipur, Kolkata, Madurai, Puducherry
2022-12-29
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Ahmedabad, Belagavi, Chennai, Dehradun, Gurgaon, Gurugram, Hyderabad, Kanpur
2022-12-13
Active, closed
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
594
Jaipur, Pune, Surat
2022-09-15
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
AstraZeneca
Phase 3
644
Bangalore, Jaipur, Kolkata, Nagpur, Nashik, New Delhi, Puducherry, Vadodara
2022-05-16
By invitation
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
NCT05303532Cancer
AstraZeneca
Phase 3
214
Chennai
2022-04-19
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Ahmedabad, Bangalore, Delhi, Hyderabad, Jaipur, Kolkata, Mumbai, New Delhi
2022-03-28
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Bikaner, Meerut, Mohali, New Delhi
2022-03-25
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Ahmedabad, Bangalore, Delhi, Howrah, Hyderabad, Jaipur, Kolkata, Marg Jaipur
2022-02-18
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
AstraZeneca
Phase 3
363
Ahmedabad, Dehradun, Delhi, Hyderabad, Kolkata, Nadiฤd, Pune, Secunderabad
2022-02-15
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
454
Bangalore, Delhi, Hyderabad, Mumbai, Nashik
2021-10-28
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
AstraZeneca
Phase 3
148
Bangalore, Belagavi, Jaipur, Mysore, Nashik
2021-10-28
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
AstraZeneca
Phase 3
927
Gurgaon, Howrah, Nagpur, Nashik, New Delhi, Raipur, Rishikesh, Surat
2021-10-25
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
AstraZeneca
Phase 3
732
Gurgaon, Howrah, Hyderabad, Jaipur, Kolkata, Nashik, Surat, Visakhapatnam
2021-10-18
Active, closed
D9319C00001- 1L OC Mono Global RCT
NCT04884360Ovarian Cancer
AstraZeneca
Phase 3
366
Gurgaon, Jaipur, Kolkata, Madurai, Namakkal, Nashik, New Delhi
2021-05-31
Active, closed
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
893
Bangalore, Mohali, Mysuru, Nagpur, New Delhi, Vadodara, Varanasi
2021-05-10
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
AstraZeneca
Phase 3
1,157
Ahmedabad, Bangalore, Bengaluru, Calicut, Gurgaon, Mysuru, Nashik, New Delhi
2021-04-26
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
1,370
Ahmedabad, Calicut, Delhi, Faridabad, Gurgaon, Karamsad, Kolkata, Madurai
2021-01-28
Active, closed
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
NCT04538742Metastatic Breast Cancer
AstraZeneca
Phase 1/2
245
Delhi, Gurgaon, Madurai, Mumbai
2020-12-28
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
358
Mumbai, Namakkal, New Delhi, Varanasi
2020-12-16
Active, closed
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
NCT04606771Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
30
Delhi, Mumbai
2020-09-28
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca
Phase 2
477
Delhi, Gurgaon, Kolkata, Mumbai
2020-08-18
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 3
866
Bengaluru, Calicut, Kolkata, Marg Jaipur, New Delhi, Surat, Thiruvananthapuram
2020-07-24
Active, closed
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
NCT04191304Hypereosinophilic Syndrome
AstraZeneca
Phase 3
134
Ahmedabad, Ajmer, Delhi
2020-07-20
Active, closed
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853Hormone-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,012
Ahmedabad, Bangalore, Delhi, Faridabad, Kanpur, Kolkata, Madurai, Manipal
2020-07-13
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
AstraZeneca
Phase 3
805
Hisar, Mumbai
2020-05-05
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
587
Belagavi, Bengaluru, Gurgaon, Kolkata, New Delhi, Pune
2019-07-02
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
AstraZeneca
Phase 3
923
Bangalore, Gurgaon, Kolkata, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2019-06-25
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
AstraZeneca
Phase 3
908
Bangalore, Hyderabad, Kolkata, Mumbai, New Delhi
2019-04-29
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
AstraZeneca
Phase 3
810
Gurgaon, Kolkata, Mumbai, New Delhi
2019-04-16
Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407Hyperkalaemia
AstraZeneca
Phase 3
140
Bhubaneswar, Gurgaon, New Delhi
2019-04-02
Active, closed
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT03778229Carcinoma
AstraZeneca
Phase 2
367
Bangalore, Chennai, Kolkata, New Delhi
2019-01-09
Active, closed
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
NCT03775486Non-small Cell Lung Cancer NSCLC
AstraZeneca
Phase 2
401
Ahmedabad, Jamnagar, Kochi, Mysuru, Nashik, Pune, Thiruvananthapuram
2018-12-21
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
825
Ahmedabad, Gurgaon, Kolkata, Manipal, Mumbai, Mysuru, Namakkal, Nashik
2018-12-06
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
AstraZeneca
Phase 3
724
Bangalore, Bengaluru, Hyderabad, Kolkata, Madurai, Mumbai, Nashik, Pune
2018-11-30
Active, closed
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
NCT03706690Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
407
Bangalore, Bengaluru, Karamsad, Kolkata, Nashik, Vadodara
2018-11-27
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
AstraZeneca
Phase 3
1,246
Gurgaon, Hubli, Kolkata, Mysuru, Nagpur, Nashik, New Delhi, Pune
2018-09-27
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
AstraZeneca
Phase 3
730
Bengaluru, Gurgaon
2018-09-27
Active, closed
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
NCT03521154Non Small Cell Lung Cancer (Stage III)
AstraZeneca
Phase 3
216
Bangalore, Gurgaon, Hubli, Karamsad, Kolkata, Nashik, New Delhi
2018-07-19
Recruiting
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
NCT03549754Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
AstraZeneca
Observational
35,000
Ahmedabad, Kolkata, Mumbai
2018-02-17
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,324
Bangalore, Bhubneshwar, Chennai, Hubli, Hyderabad, Karmsad, Mumbai, Nashik
2017-10-11
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
AstraZeneca
Phase 3
953
Ahmedabad, Bangalore, Chennai, Gurgaon, Karamsad, New Delhi
2015-11-03
Active, closed
Comparison of Fulvestrant (FASLODEXโ„ข) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437Breast Cancer
AstraZeneca
Phase 3
736
Ansฤrinagar, Bhopal, Hyderabad, Jaipur, Kolkata, Manipal, Marg Jaipur, Mumbai
2005-02-13
Rows per page Showing 1–100 of 100
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-india

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.